Therefore, PCSK9 inhibitors are primarily used for secondary prevention in patients with T2D, with a history of CVD, who are unable to achieve optimal LDL-C levels on maximally tolerated statin therapy [45]. Here, PCSK9 is linked to type 2 diabetes mellitus.